학술논문
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Document Type
article
Author
Source
npj Vaccines, Vol 6, Iss 1, Pp 1-6 (2021)
Subject
Language
English
ISSN
2059-0105
31769225
31769225
Abstract
Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.